Testosterone Cypionate

On June 18, 2026, FDA/HHS announced requested testosterone-label revisions covering the age-related hypogonadism limitation and prostate warnings. This was a labeling-change request; older product labels still carry differing wording. It does not establish approval for performance use.^[3][4]

Jurisdiction

United States

Product

Testosterone replacement products covered by the FDA request

Indication

Testosterone replacement; requested label changes, not a performance indication

Record date

2026-09-08

• US regulatory context; a class communication does not establish the approval status of every ester or international blend.

The cypionate label specifically says testosterone cypionate and testosterone propionate are not interchangeable because their durations differ. A cypionate half-life cannot verify a propionate half-life.^[2]

• The inspected source supplies no numerical propionate half-life.

TRAVERSE found testosterone gel noninferior to placebo for major cardiovascular events in selected men with hypogonadism and cardiovascular risk; atrial fibrillation, acute kidney injury and pulmonary embolism occurred more often in the testosterone arm. This was a gel-replacement trial, not an injectable-AAS misuse trial.^[5]

• Formulation and clinical population differ from injectable or supraphysiologic nonmedical use.
• Abstract-checked; no qualified clinical review.

A study of male weightlifters associated long-term mixed AAS exposure with lower left-ventricular function and greater coronary plaque volume than in non-users. The observational design cannot isolate an individual steroid or prove a precise risk of heart attack.^[6]

• Class-context evidence from selected male weightlifters; residual confounding and uncertain historical exposures remain.

The HAARLEM echocardiography cohort found increased left-ventricular mass and reduced function during mixed AAS use, with measured group parameters returning to baseline at follow-up. Only 25 of 31 participants had recovery imaging; this cannot promise that every person or repeated exposure recovers.^[7]

• Small cohort, coexposures and missing follow-up; no clinical-event or molecule-specific risk estimate.

In February 2025, FDA required testosterone-label warnings about increased blood pressure after ambulatory monitoring studies. Removal of earlier major-cardiovascular-event boxed-warning language did not mean that testosterone had no cardiovascular effects.^[8]

• Product-specific warnings and clinical context remain relevant; this communication does not establish safety of supraphysiologic use.

A cross-sectional study of male weightlifters associated long-term illicit AAS use with impaired cardiac function and more coronary plaque. The study cannot establish the risk from one particular compound, dose or combination.^[9]

• Observational evidence, self-reported mixed exposures and potential confounding; not a comparison of medically indicated testosterone treatment.

FDA reports serious liver injury and other serious reactions involving steroid or steroid-like bodybuilding products. It advises prompt discussion with a healthcare professional, including before abrupt cessation because withdrawal can be dangerous.^[10]

• General product safety communication, not an incidence estimate for every listed steroid.

In the HAARLEM cohort of men using mixed anabolic-androgenic steroids, testosterone and sperm recovery varied; some still had abnormal results at follow-up. Testosterone concentration and sperm production are different outcomes, and no universal recovery deadline follows from this cohort.^[1]

• Class-context evidence: mixed exposures cannot isolate any individual molecule or ester, and follow-up was too short to characterize all recovery.
• Abstract-checked; no qualified clinical review.

The inspected intramuscular testosterone-cypionate label gives an approximate eight-day half-life. The estimate concerns an oil depot and should not be generalized to other testosterone formulations.^[2]

• Product- and route-specific label estimate; not a washout or endocrine-recovery schedule.

Long-term illicit AAS exposure was associated with myocardial dysfunction and greater coronary plaque in male weightlifters. Concern about combining AAS follows from this class evidence; the incremental risk of any two steroids was not measured.^[9]

• Observational, mixed self-reported exposure; no pair-specific causal estimate.

FDA warns that combining steroid-like bodybuilding products with other products, including stimulants, may increase serious-reaction risk. This broad warning does not establish the effect or severity of an individual compound pair.^[10]

• This evidence does not establish the magnitude or frequency of harm from the selected combination.

A review of testosterone-treatment studies found increased hemoglobin and hematocrit. Extrapolating to combined anabolic steroids suggests a possible overlapping effect, but the review did not establish pair-specific thrombosis risk.^[11]

• This evidence does not establish the magnitude or frequency of harm from the selected combination.

Testosterone-related hematocrit increases and tamoxifen/raloxifene thromboembolic findings come from different study populations. They motivate a possible overlapping concern, not evidence of a measured thrombosis increase from the selected pair.^[11][12]

• This evidence does not establish the magnitude or frequency of harm from the selected combination.

A controlled study in men linked estrogen deficiency to increased body fat and a contribution to reduced sexual function. It does not establish the outcome of combining aromatase inhibitors or adding one to a particular anabolic steroid.^[13]

• This evidence does not establish the magnitude or frequency of harm from the selected combination.